{"id":5461,"date":"2026-07-23T18:34:21","date_gmt":"2026-07-23T18:34:21","guid":{"rendered":"https:\/\/echeloncreativemedia.com\/marketvows\/2026\/07\/23\/eli-lilly-eyes-2027-approval-for-next-gen-obesity-drug-retatrutide-after-landmark-trial-success\/"},"modified":"2026-07-23T18:34:21","modified_gmt":"2026-07-23T18:34:21","slug":"eli-lilly-eyes-2027-approval-for-next-gen-obesity-drug-retatrutide-after-landmark-trial-success","status":"publish","type":"post","link":"https:\/\/echeloncreativemedia.com\/marketvows\/2026\/07\/23\/eli-lilly-eyes-2027-approval-for-next-gen-obesity-drug-retatrutide-after-landmark-trial-success\/","title":{"rendered":"Eli Lilly Eyes 2027 Approval for Next-Gen Obesity Drug &#8216;Retatrutide&#8217; After Landmark Trial Success"},"content":{"rendered":"<p>Eli Lilly announced it will seek approval for its next-generation obesity drug, retatrutide, in Q1 2027, following positive results from two new late-stage trials. The drug has shown significant weight loss and improved blood sugar control in adults with obesity and related conditions like Type 2 diabetes and cardiovascular disease. Lilly cited the need for more manufacturing and quality control data as the reason for the adjusted timeline.<\/p>\n<p>Retatrutide, dubbed the &#8220;triple G&#8221; drug for its multi-hormonal action (GLP-1, GIP, and glucagon), has demonstrated superior efficacy compared to current treatments. Positive outcomes from five late-stage trials position it as a key player in Lilly&#8217;s growing obesity portfolio and a significant contender in the booming weight-loss drug market.<\/p>\n<p><\/p>\n<p style=\"text-align: left;font-style: normal;font-weight: bold\"><a href=\"https:\/\/www.cnbc.com\/2026\/05\/21\/eli-lilly-obesity-drug-retatrutide-2027-approval.html\" target=\"_blank\" rel=\"noopener noreferrer\">READ MORE FROM CNBC<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly announced it will seek approval for its next-generation obesity drug, retatrutide, in Q1 2027, following positive results from two new late-stage trials. The drug has shown significant weight loss and improved blood sugar control in adults with obesity and related conditions like Type 2 diabetes and cardiovascular disease. Lilly cited the need for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5462,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/media-cldnry.s-cn-us-1.ssl.fastly.net\/image\/fetch\/c_fill,w_778,h_438,q_auto,f_auto\/https%3A%2F%2Fmedia.cnbc.com%2Fassets%2Fimages%2Fmedia%2Flogo%2Feli-lilly-logo.preset.jpg","fifu_image_alt":"","footnotes":""},"categories":[29],"tags":[],"class_list":["post-5461","post","type-post","status-publish","format-standard","has-post-thumbnail","category-global-affairs","rifnote_executive-kenneth-custer"],"fifu_image_url":"https:\/\/media-cldnry.s-cn-us-1.ssl.fastly.net\/image\/fetch\/c_fill,w_778,h_438,q_auto,f_auto\/https%3A%2F%2Fmedia.cnbc.com%2Fassets%2Fimages%2Fmedia%2Flogo%2Feli-lilly-logo.preset.jpg","_links":{"self":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/posts\/5461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/comments?post=5461"}],"version-history":[{"count":0,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/posts\/5461\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/media\/5462"}],"wp:attachment":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/media?parent=5461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/categories?post=5461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/tags?post=5461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}